Key result
Initial rituximab for Asian-variant intravascular lymphoma triggers severe pulmonary complications in all 3 treated patients.
Case Report (n=3)
No
Patients with the Asian variant of intravascular lymphoma require careful monitoring for severe pulmonary complications during initial rituximab treatment.
Answers are grounded in this paper and cite their sources.
Initial rituximab risks acute respiratory distress in Asian-variant intravascular lymphoma; leaves open safer induction strategies for this rare entity.
Rituximab improves response to treatment and outcome for patients with CD20+ B-cell lymphoma. Herein, however, we report the occurrence of severe pulmonary complications shortly after rituximab infusion in three patients with the newly diagnosed Asian variant of intravascular lymphoma. It is suggested that patients with this subtype of lymphoma are monitored carefully for possible drug reactions during the use of rituximab.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2007) conducted a case report in Asian-variant of intravascular lymphoma (n=3). Rituximab was evaluated on Severe pulmonary complications. Rituximab infusion as initial treatment for the Asian-variant of intravascular lymphoma caused severe pulmonary complications, including acute respiratory distress, in all three treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: